Universität zu Köln

Spiro, J., Maintz, D. and Persigehl, T. (2015). Response criteria for malignant melanoma. RECIST and irRC. Radiologe, 55 (2). S. 127 - 136. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-2102

Full text not available from this repository.

Abstract

In the field of oncology the response evaluation criteria in solid tumors (RECIST) currently represent the most commonly used and validated radiological response criteria for objective treatment monitoring of conventional chemotherapy. For therapy monitoring of classical cytostatic and cytotoxic tumor therapies RECIST has been tested and successfully validated in many clinical studies. However, with the introduction of novel molecular drugs limitations of these size-based criteria became obvious due to response patterns which are not reflected by RECIST. Thus, for a comprehensive evaluation of modern immunotherapeutic agents new immune-related response criteria (irRC) were developed. This review gives a brief overview of the most important radiological response criteria RECIST 1.0 and 1.1 as well as irRC for malignant melanoma.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Spiro, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Maintz, D. UNSPECIFIED UNSPECIFIED UNSPECIFIED Persigehl, T. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-413207
DOI:	10.1007/s00117-014-2763-y
Journal or Publication Title:	Radiologe
Volume:	55
Number:	2
Page Range:	S. 127 - 136
Date:	2015
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-2102
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SOLID TUMORS; GUIDELINES; THERAPY Multiple languages Radiology, Nuclear Medicine & Medical Imaging Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/41320